View Older Stories

Jan 29, 2026 04:44AM Goldman Sachs Reiterates Sell Rating on Halozyme Therapeutics (HALO)

Jan 28, 2026 06:41AM Halozyme provides preliminary 2025 revenue estimates

Jan 8, 2026 09:30AM Halozyme Therapeutics (HALO) PT Raised at TD Cowen; 'One of Our Top Picks for 2026'

Dec 5, 2025 05:18AM Halozyme (HALO) Has Compelling Upside Driver in MDASE royalty - Citizens

Dec 4, 2025 01:28PM German court grants HALOZYME injunction against Merck's Keytruda SC

Dec 4, 2025 06:51AM Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Sell 'as we approach peak revenue'

Nov 28, 2025 06:34AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Nov 17, 2025 11:21AM Halozyme Therapeutics (HALO) PT Raised to $56 at Goldman Sachs

Nov 7, 2025 08:31AM FDA approves DARZALEX Faspro for high-risk smoldering multiple myeloma

Nov 4, 2025 05:03AM Halozyme Therapeutics (HALO) PT Raised to $92 at Citizens on Strong Quarter

Nov 3, 2025 04:02PM Halozyme Therapeutics (HALO) Tops Q3 EPS by 11c, provides guidance

Oct 21, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Oct 14, 2025 01:26PM Leerink Partners Upgrades Halozyme Therapeutics (HALO) to Market Perform

Oct 2, 2025 06:42AM Halozyme Therapeutics (HALO) PT Raised to $90 at H.C. Wainwright

Oct 2, 2025 04:28AM Halozyme Therapeutics (HALO) PT Raised to $70 at Leerink Partners

Oct 1, 2025 01:20PM Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'

Oct 1, 2025 01:13PM FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'

Oct 1, 2025 04:21AM Citizens JMP Reiterates Market Outperform Rating on Halozyme Therapeutics (HALO)

Sep 24, 2025 08:20AM Halozyme Therapeutics (HALO) PT Raised to $90 at Benchmark Following Strong Earnings, Guidance

Sep 22, 2025 06:42AM Halozyme Therapeutics (HALO) PT Raised to $85 at H.C. Wainwright

Aug 12, 2025 04:59AM Halozyme Therapeutics (HALO) PT Raised to $56 at Goldman Sachs

Aug 6, 2025 04:08AM Halozyme Therapeutics (HALO) PT Raised to $91 at Citizens JMP

Aug 6, 2025 03:37AM Morgan Stanley Upgrades Halozyme Therapeutics (HALO) to Overweight

Aug 5, 2025 04:05PM Halozyme Therapeutics (HALO) Tops Q2 EPS by 30c ; Offers Guidance

Jul 23, 2025 11:39AM European Commission approves Halozyme's DARZALEX Faspro for smouldering multiple myeloma

Jul 10, 2025 06:28AM Goldman Sachs Resumes Halozyme Therapeutics (HALO) at Neutral

Jun 30, 2025 04:07PM Halozyme Therapeutics (HALO) added to Russell 1000

Jun 20, 2025 01:15PM Halozyme Therapeutics (HALO) Announces argenx Received European Commission Approval for VYVGART Subcutaneous Injection with ENHANZE

Jun 10, 2025 10:00AM TD Cowen on Halozyme Therapeutics (HALO): 'Potential CMS Impact Analysis Reaffirms Our Buy Rating'

May 29, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

May 28, 2025 08:31AM Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb (BMY) Received European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE

May 14, 2025 04:50AM Increasing unusual call option volume: PSX XLI HALO ARRY SATS SHLS AVTR

May 14, 2025 04:13AM Citizens JMP Reiterates Market Outperform Rating on Halozyme Therapeutics (HALO)

May 14, 2025 03:12AM Morgan Stanley Downgrades Halozyme Therapeutics (HALO) to Equalweight

May 13, 2025 02:44PM Evercore ISI Reiterates Outperform Rating on Halozyme Therapeutics (HALO)

May 13, 2025 08:50AM Leerink Partners Downgrades Halozyme Therapeutics (HALO) to Underperform 'On CMS Action'

May 7, 2025 10:47AM Benchmark Reiterates Hold Rating on Halozyme Therapeutics (HALO)

May 6, 2025 11:36PM Halozyme Therapeutics (HALO) PT Raised to $79 at TD Cowen

May 6, 2025 04:17PM Halozyme Therapeutics (HALO) Tops Q1 EPS by 13c, provides guidance

Apr 28, 2025 07:31AM Halozyme Therapeutics (HALO) Announces argenx Received Positive CHMP Opinion for VYVGART

Apr 25, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Apr 24, 2025 08:34AM Halozyme Therapeutics (HALO) Sues Merck (MRK) for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 21, 2025 06:41AM Firms face COVID-level uncertainty amid Trump tariffs - Morgan Stanley

Apr 9, 2025 08:45AM Halozyme Therapeutics (HALO) Announces EU Approval of Subcutaneous DARZALEX-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligi

Apr 7, 2025 09:29AM Halozyme Therapeutics (HALO) Announces EU Approval of Subcutaneous RYBREVANT

Mar 31, 2025 08:31AM Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo with ENHANZE

Mar 6, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)

Mar 6, 2025 04:30AM Citizens JMP Reiterates Market Outperform Rating on Halozyme Therapeutics (HALO)

Feb 19, 2025 06:56AM Halozyme Therapeutics (HALO) PT Raised to $72 at H.C. Wainwright

Feb 19, 2025 04:37AM Halozyme Therapeutics (HALO) PT Raised to $78 at Citizens JMP

View Older Stories